Suppr超能文献

鼠源调节性 T 细胞包含具有不同 ICOS 表达的高增殖和易死亡亚群。

Murine regulatory T cells contain hyperproliferative and death-prone subsets with differential ICOS expression.

机构信息

Division of Allergy and Immunology, Department of Pediatrics, Duke University Medical Center, Durham, NC 27710, USA.

出版信息

J Immunol. 2012 Feb 15;188(4):1698-707. doi: 10.4049/jimmunol.1102448. Epub 2012 Jan 9.

Abstract

Regulatory T cells (Treg) are crucial for self-tolerance. It has been an enigma that Treg exhibit an anergic phenotype reflected by hypoproliferation in vitro after TCR stimulation but undergo vigorous proliferation in vivo. We report in this study that murine Treg are prone to death but hyperproliferative in vitro and in vivo, which is different from conventional CD4(+)Foxp3(-) T cells (Tcon). During in vitro culture, most Treg die with or without TCR stimulation, correlated with constitutive activation of the intrinsic death pathway. However, a small portion of the Treg population is more sensitive to TCR stimulation, particularly weak stimulation, proliferates more vigorously than CD4(+) Tcon, and is resistant to activation-induced cell death. Treg proliferation is enhanced by IL-2 but is less dependent on CD28-mediated costimulation than that of Tcon. We demonstrate further that the surviving and proliferative Treg are ICOS(+) whereas the death-prone Treg are ICOS(-). Moreover, ICOS(+) Treg contain much stronger suppressive activity than that of ICOS(-) Treg. Our data indicate that massive death contributes to the anergic phenotype of Treg in vitro and suggest modulation of Treg survival as a therapeutic strategy for treatment of autoimmune diseases and cancer.

摘要

调节性 T 细胞(Treg)对于自身耐受至关重要。一个谜是,Treg 在体外 TCR 刺激后表现出增殖能力低下的无能表型,但在体内却经历强烈的增殖。我们在本研究中报告称,与传统的 CD4(+)Foxp3(-)T 细胞(Tcon)不同,鼠 Treg 容易死亡但在体外和体内呈高增殖状态。在体外培养过程中,大多数 Treg 在有无 TCR 刺激的情况下都会死亡,这与内在死亡途径的组成性激活有关。然而,一小部分 Treg 群体对 TCR 刺激更为敏感,特别是弱刺激,比 CD4(+)Tcon 更强烈地增殖,并且对活化诱导的细胞死亡具有抗性。IL-2 增强了 Treg 的增殖,但比 Tcon 对 CD28 介导的共刺激的依赖性更低。我们进一步证明,存活和增殖的 Treg 是 ICOS(+),而易于死亡的 Treg 是 ICOS(-)。此外,ICOS(+)Treg 比 ICOS(-)Treg 具有更强的抑制活性。我们的数据表明,大量死亡导致了 Treg 在体外的无能表型,并提示调节 Treg 存活可作为治疗自身免疫性疾病和癌症的一种治疗策略。

相似文献

1
Murine regulatory T cells contain hyperproliferative and death-prone subsets with differential ICOS expression.
J Immunol. 2012 Feb 15;188(4):1698-707. doi: 10.4049/jimmunol.1102448. Epub 2012 Jan 9.
2
Dominant role of antigen dose in CD4+Foxp3+ regulatory T cell induction and expansion.
J Immunol. 2009 Oct 15;183(8):4895-903. doi: 10.4049/jimmunol.0901459.
4
KLRG1 expression identifies short-lived Foxp3 T effector cells with functional plasticity in islets of NOD mice.
Autoimmunity. 2017 Sep;50(6):354-362. doi: 10.1080/08916934.2017.1364368. Epub 2017 Aug 29.
6
Id1 expression promotes T regulatory cell differentiation by facilitating TCR costimulation.
J Immunol. 2014 Jul 15;193(2):663-672. doi: 10.4049/jimmunol.1302554. Epub 2014 Jun 11.
7
Two functional subsets of FOXP3+ regulatory T cells in human thymus and periphery.
Immunity. 2008 Jun;28(6):870-80. doi: 10.1016/j.immuni.2008.03.018. Epub 2008 May 29.
9
mTORC1 couples immune signals and metabolic programming to establish T(reg)-cell function.
Nature. 2013 Jul 25;499(7459):485-90. doi: 10.1038/nature12297. Epub 2013 Jun 30.
10

引用本文的文献

1
Regulatory T cells in the tumour microenvironment.
Nat Rev Cancer. 2025 Jun 10. doi: 10.1038/s41568-025-00832-9.
4
Enriched circulating and tumor-resident TGF-β regulatory B cells in patients with melanoma promote FOXP3 Tregs.
Oncoimmunology. 2022 Jul 28;11(1):2104426. doi: 10.1080/2162402X.2022.2104426. eCollection 2022.
5
The immune checkpoint ICOSLG is a relapse-predicting biomarker and therapeutic target in infant t(4;11) acute lymphoblastic leukemia.
iScience. 2022 Jun 16;25(7):104613. doi: 10.1016/j.isci.2022.104613. eCollection 2022 Jul 15.
6
CD38 Correlates with an Immunosuppressive Treg Phenotype in Lupus-Prone Mice.
Int J Mol Sci. 2021 Nov 5;22(21):11977. doi: 10.3390/ijms222111977.
7
Dual targeting of CTLA-4 and CD47 on T cells promotes immunity against solid tumors.
Sci Transl Med. 2021 Aug 4;13(605). doi: 10.1126/scitranslmed.abg8693.
8
ICOS Tregs: A Functional Subset of Tregs in Immune Diseases.
Front Immunol. 2020 Aug 28;11:2104. doi: 10.3389/fimmu.2020.02104. eCollection 2020.
10
Immunomodulatory Strategies Targeting Dendritic Cells to Improve Corneal Graft Survival.
J Clin Med. 2020 Apr 28;9(5):1280. doi: 10.3390/jcm9051280.

本文引用的文献

2
Negative regulation of mTOR activation by diacylglycerol kinases.
Blood. 2011 Apr 14;117(15):4022-31. doi: 10.1182/blood-2010-08-300731. Epub 2011 Feb 10.
3
mTOR: from growth signal integration to cancer, diabetes and ageing.
Nat Rev Mol Cell Biol. 2011 Jan;12(1):21-35. doi: 10.1038/nrm3025. Epub 2010 Dec 15.
4
An oscillatory switch in mTOR kinase activity sets regulatory T cell responsiveness.
Immunity. 2010 Dec 14;33(6):929-41. doi: 10.1016/j.immuni.2010.11.024. Epub 2010 Dec 9.
5
Receptor signaling in immune cell development and function.
Immunol Res. 2011 Apr;49(1-3):109-23. doi: 10.1007/s12026-010-8175-9.
6
Melanoma cells express ICOS ligand to promote the activation and expansion of T-regulatory cells.
Cancer Res. 2010 Dec 1;70(23):9581-90. doi: 10.1158/0008-5472.CAN-10-1379. Epub 2010 Nov 23.
7
A major role for Bim in regulatory T cell homeostasis.
J Immunol. 2011 Jan 1;186(1):156-63. doi: 10.4049/jimmunol.1001505. Epub 2010 Nov 22.
8
Inducible costimulator (ICOS) is a marker for highly suppressive antigen-specific T cells sharing features of TH17/TH1 and regulatory T cells.
J Allergy Clin Immunol. 2010 Aug;126(2):280-9, 289.e1-7. doi: 10.1016/j.jaci.2010.05.022. Epub 2010 Jul 10.
9
Regulatory T cells as therapeutic targets in rheumatoid arthritis.
Nat Rev Rheumatol. 2009 Oct;5(10):560-5. doi: 10.1038/nrrheum.2009.183.
10
Differential responses of human regulatory T cells (Treg) and effector T cells to rapamycin.
PLoS One. 2009 Jun 22;4(6):e5994. doi: 10.1371/journal.pone.0005994.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验